Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Project details

British Biomedicine R&D firm with new drug against MRSA looking for investors

Project region Britain, United Kingdom
Industry Healthcare
Total value of the target N/A
Expected target net rate of return after deducting all taxes and fees N/A
Validity period of pending order 365

CONTACT ADVISOR

  • Simon Laube

    Simon Laube

    Senior Associate, International Business Advisory

Project highlights The market value is 19 million pounds.
Project description

The company has developed a new anti-infection drug with outstanding and rapid bacterial activity against Staphylococcus aureus (SA), which is the biggest cause of nosocomial bacterial infection in the world. The leading drug has completed clinical trials funded by the US government. Different from traditional antibiotics, this drug shows excellent resistance to SA bacteria in the laboratory where it has produced a series of low bacterial resistance potentials, and can be used to prevent and treat MRSA infection. The company has been listed on the Alternative Investment Market (AIM), a sub-market of London Stock Exchange (LSE), with a market value of 19 million pounds.

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive